Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib

被引：1

作者：

Mok, T. S. K. ^{[1
]}

Liu, G. ^{[2
]}

Nyaw, S. F. ^{[3
]}

Curcio, H. ^{[4
]}

Cortot, A. ^{[5
]}

Kam, T. Y. ^{[6
]}

Descourt, R. ^{[7
]}

Chik, Y. K. ^{[8
]}

Cheema, P. K. ^{[9
]}

Gwinnutt, J. M. ^{[10
]}

Churchill, E. N. ^{[11
]}

Nyborn, J. ^{[12
]}

Curran, E. ^{[13
]}

Yin, Y. ^{[14
]}

Chong, K. ^{[15
]}

Tanaka-Chambers, Y. ^{[16
]}

Kretz, J. ^{[17
]}

Cadranel, J. ^{[18
,19
]}

机构：

[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Peoples R China

[2] Princess Margaret Canc Ctr, Ontario Canc Inst, Med Oncol, Toronto, ON, Canada

[3] Tuen Mun Hosp, Dept Clin Oncol, Hong Kong, Peoples R China

[4] Ctr Francois Baclesse, Oncol Dept, Caen, France

[5] CHRU Lille, Dept Thorac Oncol, Lille, France

[6] Pamela Youde Nethersole Eastern Hosp Main Block, Dept Clin Oncol, Hong Kong, Peoples R China

[7] CHU Brest, Oncol Dept, Hop Morvan, Brest, France

[8] Queen Elizabeth Hosp QEH, Dept Clin Oncol, Hong Kong, Peoples R China

[9] Univ Toronto, William Osler Hlth Syst, Oncol, Brampton, ON, Canada

[10] IQVIA, Global Epidemiol, Reading, Berks, England

[11] Takeda Pharmaceut USA Inc, Global Med Affairs Oncol, Lexington, MA USA

[12] Takeda Dev Ctr Amer Inc, Global Med Affairs Oncol, Cambridge, MA USA

[13] Takeda Dev Ctr Amer Inc, Global Evidence & Outcome Res, Lexington, MA USA

[14] Takeda Dev Ctr Amer Inc, Observat Res Analyt, Lexington, MA USA

[15] Takeda Dev Ctr Amer Inc, Clin Data Management, Cambridge, MA USA

[16] Takeda Pharmaceut, Stat & Quantitat Sci, Cambridge, MA USA

[17] Takeda Pharmaceut Int AG, Dept Thorac Oncol, Glattpark Opfikon, Zurich, Switzerland

[18] Hop Tenon, AP HP, Pulmonol & Thorac Oncol Dept, Paris, France

[19] Sorbonne Univ Paris, Paris, France

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.663

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

585P

引用

页码：S1698 / S1699

页数：2